NCT02014844View on ClinicalTrials.gov

Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Glioblastoma
Interventions
DRUG

250 mg/m2 aldoxorubicin

DRUG

350 mg/m2 aldoxorubicin

Trial Locations (4)

78705

Texas Oncology-Austin Midtown, Austin

90403

Sarcoma Oncology Center, Santa Monica

91010

City of Hope National Medical Center, Duarte

70115-6969

Ochsner Health System, New Orleans

Sponsors

Lead Sponsor

ImmunityBio, Inc.
All Listed Sponsors
lead

ImmunityBio, Inc.

INDUSTRY